Millennium Pharmaceuticals Limited

Natalia Iartchouk

Gordon B Mills

Robert C Bast

Mark David Ayers

Edwin A Clark

Lynn C Hartmann

Andrew I Damokosh

Jeffrey L Brown

Karen Lu

James J Stec, Ii

The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.

Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of 'sensitivity markers.' These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of 'resistance markers.' These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

Compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Growing community of inventors

Wayland, MA, United States of America

Natalia Iartchouk